
SENORES
Senores Pharmaceuticals Limited
- IPO Status
- Closed
- Open Date
- 20 Dec 2024
- Close Date
- 24 Dec 2024
IPO Details
- Min. Investment
- ₹14,858
- Price Band
- ₹372 - ₹391
- Lot Size
- 38 shares
- Issue Size
- ₹582 Cr
- Face Value
- 10
- IPO Doc
- —
Schedule
- IPO open20 Dec 2024
- IPO close date24 Dec 2024
- Allotment date26 Dec 2024
- Funds unblock or debit26 Dec 2024
- Listing date30 Dec 2024
Financial Performance
- Revenue
- Profit
Stocks similar to SENORES
- Ajanta Pharma Ltd
- Alembic Pharmaceuticals Ltd
- Caplin Point Laboratories Ltd
- Gland Pharma Ltd
- Strides Pharma Science Ltd
FAQs
Senores Pharmaceuticals Limited IPO is a Mainboard IPO aggregating up to ₹582 Cr, with equity shares of face value ₹10 each. The shares are proposed to be listed on NSE.
The Senores Pharmaceuticals Limited IPO opened on 20 Dec 2024 and closed on 24 Dec 2024. IPO Period: 20 Dec 2024 – 24 Dec 2024.
The price band for the Senores Pharmaceuticals Limited IPO is ₹372 to ₹391 per share. Investors can bid within the specified price band, subject to the applicable IPO rules.
The minimum lot size is 38 shares. At the upper price band of ₹391, the minimum investment required is ₹14,858.
Particular Details Lot Size 38 shares Price Band ₹372 – ₹391 Minimum Investment ₹14,858 Maximum Retail Lots 13 Here is the timeline for the Senores Pharmaceuticals Limited IPO:
IPO Event Date IPO Opens 20 Dec 2024 IPO Closes 24 Dec 2024 UPI Mandate Deadline 24 Dec 2024, 5:00 PM Basis of Allotment 26 Dec 2024 Refund Initiation 26 Dec 2024 Shares Credited 27 Dec 2024 Listing Date 30 Dec 2024 The basis of allotment for the Senores Pharmaceuticals Limited IPO is expected to be finalised on 26 Dec 2024. Investors can check their allotment status through the registrar or relevant stock exchange website using their application details. Registrar: Link Intime.
The equity shares of Senores Pharmaceuticals Limited are proposed to be listed on NSE. Proposed Listing Date: 30 Dec 2024.
The key financial performance of Senores Pharmaceuticals Limited is:
Financial Year Revenue Profit FY23 ₹35.34 Cr ₹8.43 Cr FY24 ₹214.52 Cr ₹31.46 Cr FY25 ₹398.25 Cr ₹58.56 Cr Revenue CAGR: 235.7% | Profit CAGR: 163.6%. Figures are as disclosed in the company's offer documents.


